CD40 pathway activation status predicts response to CD40 therapy in diffuse large B cell lymphoma.
about
Improving Adoptive T Cell Therapy: The Particular Role of T Cell Costimulation, Cytokines, and Post-Transfer VaccinationPilot study of dacetuzumab in combination with rituximab and gemcitabine for relapsed or refractory diffuse large B-cell lymphoma.A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors.PAK1 mediates resistance to PI3K inhibition in lymphomas.Over-expression of Thioredoxin-1 mediates growth, survival, and chemoresistance and is a druggable target in diffuse large B-cell lymphoma.Robust enumeration of cell subsets from tissue expression profilesAgonistic CD40 antibodies and cancer therapy.A novel class of piperidones exhibit potent, selective and pro-apoptotic anti-leukemia properties.Tumor-selective cytotoxicity of a novel pentadiene analogue on human leukemia/ lymphoma cellsPhase IA/II, multicentre, open-label study of the CD40 antagonistic monoclonal antibody lucatumumab in adult patients with advanced non-Hodgkin or Hodgkin lymphoma.The use of agonistic anti-CD40 therapy in treatments for cancer.T-cell-independent antitumor effects of CD40 ligation.New therapies in non-Hodgkin lymphoma.The Central Role for Microenvironment in B-Cell Malignancies: Recent Insights into Synergistic Effects of its Therapeutic Targeting and Anti-CD20 Antibodies.The future of cancer treatment: immunomodulation, CARs and combination immunotherapy.Cancer immunotherapy: activating innate and adaptive immunity through CD40 agonists.To respond or not to respond to CD40 agonism: That is the prediction.Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications.The Use of Anti-CD40 mAb in Cancer.
P2860
Q28068378-3F3DEBF0-76A4-49C2-B997-B204F911634FQ33402203-D02D0A7B-17DE-43E2-BF7A-89F4B98585D3Q33415880-6BC80704-ADE5-4D71-926E-DE7FF1393EDBQ34539577-0EF981E0-811E-4910-B680-6879325D82B4Q35987083-7F687247-BFA3-453A-80B1-2E8CB3012F66Q36539395-FC26687D-8C89-41A8-BD9B-A1200AB1F3EEQ36664195-C96D7349-0C6F-41F6-ACFD-F34BC5C29704Q36954631-4FD151EA-A8A7-4096-B7E6-5B9AB83A47AFQ37415621-06B2F985-CC69-432E-8DCA-7C563F23689FQ37641045-F62CF5F4-BC8C-4D1C-A634-FA60C973F43FQ38026924-EFE24842-7E8B-46B4-BA53-5EB41A336337Q38026925-BA8D2962-BFE5-4710-8C76-A7254E9A1A21Q38315779-45C4243B-F43E-432F-A2D7-C55C475305E3Q38577849-E7B60321-D3F6-4E6D-B94B-708BF6568972Q38775177-5422B45E-31C9-4445-9851-2D2989F81556Q38786054-374F9E05-870E-4C6E-8510-8389AF2BF073Q42204301-FF02A73E-EF19-431D-A55C-48C47E5098A3Q47325431-66D3D241-B8B5-4BBE-BA04-D643369BA012Q53321210-D1C7EDF7-74AA-48B6-A230-19C3D66312CE
P2860
CD40 pathway activation status predicts response to CD40 therapy in diffuse large B cell lymphoma.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
CD40 pathway activation status ...... diffuse large B cell lymphoma.
@en
CD40 pathway activation status ...... diffuse large B cell lymphoma.
@nl
type
label
CD40 pathway activation status ...... diffuse large B cell lymphoma.
@en
CD40 pathway activation status ...... diffuse large B cell lymphoma.
@nl
prefLabel
CD40 pathway activation status ...... diffuse large B cell lymphoma.
@en
CD40 pathway activation status ...... diffuse large B cell lymphoma.
@nl
P2093
P2860
P1476
CD40 pathway activation status ...... diffuse large B cell lymphoma.
@en
P2093
Ajay Pandita
Allen Ebens
Andres Forero-Torres
Andrew G Polson
Bart Burington
Changchun Du
David Dornan
Dorothy French
Grazyna Fedorowicz
Hartmut Koeppen
P2860
P304
P356
10.1126/SCITRANSLMED.3001620
P407
P577
2011-03-01T00:00:00Z